Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3981] to MELK
- Suitable for: WB
- Knockout validated
- Reacts with: Human
Product nameAnti-MELK antibody [EPR3981]
See all MELK primary antibodies
DescriptionRabbit monoclonal [EPR3981] to MELK
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human MELK (N terminal). The exact sequence is proprietary.
- WB: K562, 293T, and Jurkat whole cell lysate (ab7899).
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab108529 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 75 kDa.|
FunctionPhosphorylates ZNF622 and may contribute to its redirection to the nucleus. May be involved in the inhibition of spliceosome assembly during mitosis.
Tissue specificityExpressed in placenta, kidney, thymus, testis, ovary and intestine.
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. SNF1 subfamily.
Contains 1 KA1 (kinase-associated) domain.
Contains 1 protein kinase domain.
modificationsAutophosphorylated. Thr-478 phosphorylation during mitosis promotes interaction with PPP1R8.
- Information by UniProt
- AI327312 antibody
- hMELK antibody
- HPK 38 antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: MELK knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: HCT116 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab108529 observed at 75 kDa. Red - loading control, ab8226, observed at 42 kDa.
ab108529 was shown to recognize MELK when MELK knockout samples were used, along with additional cross-reactive bands. Wild-type and MELK knockout samples were subjected to SDS-PAGE. ab108529 and ab8226 (loading control to beta Actin) were both diluted 1/1000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes : Anti-MELK antibody [EPR3981] (ab108529) at 1/1000 dilution
Lane 1 : K562 cell lysate
Lane 2 : 293T cell lysate
Lane 3 : Jurkat cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP-labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 75 kDa
ab108529 has been referenced in 10 publications.
- Zhao Y et al. Long noncoding RNA LINC02418 regulates MELK expression by acting as a ceRNA and may serve as a diagnostic marker for colorectal cancer. Cell Death Dis 10:568 (2019). PubMed: 31358735
- Giuliano CJ et al. MELK expression correlates with tumor mitotic activity but is not required for cancer growth. Elife 7:N/A (2018). PubMed: 29417930
- Wang Y et al. A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. iScience 9:149-160 (2018). PubMed: 30391850
- Li Y et al. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int 17:102 (2017). WB, IHC-P ; Human . PubMed: 29151817
- Takeuchi H et al. Phosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis. PLoS Pathog 13:e1006441 (2017). WB . PubMed: 28683086
- Lin A et al. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife 6:N/A (2017). PubMed: 28337968
- Huang HT et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife 6:N/A (2017). WB ; Human . PubMed: 28926338
- Wang Y et al. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A 113:9810-5 (2016). PubMed: 27528663
- Wang Y et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife 3:e01763 (2014). Human . PubMed: 24844244
- Kig C et al. Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. J Biol Chem 288:24200-12 (2013). WB ; Human . PubMed: 23836907